Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience

"The aim of the present study was to compare response rate between patients, underwent splenectomy vs. rituximab as second-line therapy. Adult patients diagnosed with ITP who did not respond to corticosteroids or relapsed during the period 1990-2014 were included in a quasi-experimental study. Categorical variables were compared using Fisher exact test. Response to treatment was compared using logistic regression. Data were analyzed using SAS V9.2. One-hundred and forty-three patients with ITP were identified through medical records. Of 62 patients treated..."

- From the NIH - PubMed

Read More

back to top

BBB Cleveland logo GuideStar Seal NORD Member Badge 2018THSNA logo